What is it used for?
APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- motixafortidemotixafortide
- Form and strength
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 62 mg / 1.7 mLINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 62 mg / 1.7 mL
- Manufacturer / applicant
- GAMIDA CELL INC.GAMIDA CELL INC.
For injection: 62 mg as a white to off-white lyophilized powder in a single-dose vial for reconstitution.For injection: 62 mg as a white to off-white lyophilized powder in a single-dose vial for reconstitution.
Safety and clinical review
- Anaphylactic Shock and Hypersensitivity ReactionsAnaphylactic Shock and Hypersensitivity Reactions
- Injection Site ReactionsInjection Site Reactions
- Tumor Cell Mobilization in Patients with LeukemiaTumor Cell Mobilization in Patients with Leukemia
- LeukocytosisLeukocytosis
- Potential for Tumor Cell MobilizationPotential for Tumor Cell Mobilization
- Embryo-fetal ToxicityEmbryo-fetal Toxicity
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is APHEXDA used for?
APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of APHEXDA should I ask about?
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 62 mg / 1.7 mLINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 62 mg / 1.7 mL
Read the primary sourceWhat determines the price of APHEXDA?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using APHEXDA?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.